March 2, 2018 / 1:43 PM / 6 months ago

BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea

March 2 (Reuters) - Jazz Pharmaceuticals Plc:

* JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA

* JAZZ PHARMACEUTICALS PLC - SOLRIAMFETOL ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE FOR AN FDA DECISION IS DECEMBER 20, 2018 ​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below